MedTrace Logo

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

NCT03843775 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-10-21

Study results available
· View outcomes & findings →

Summary

The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.

Conditions

  • Advanced BRAF Mutant Cancers

Interventions

DRUG

Binimetinib

Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID

DRUG

Encorafenib

encorafenib 450 mg oral QD

Sponsors & Collaborators

Principal Investigators

  • Rona Yaegar, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-14
Primary Completion
2023-09-02
Completion
2023-09-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03843775 on ClinicalTrials.gov